266 related articles for article (PubMed ID: 29317453)
1. Targeting anticoagulant protein S to improve hemostasis in hemophilia.
Prince R; Bologna L; Manetti M; Melchiorre D; Rosa I; Dewarrat N; Suardi S; Amini P; Fernández JA; Burnier L; Quarroz C; Reina Caro MD; Matsumura Y; Kremer Hovinga JA; Griffin JH; Simon HU; Ibba-Manneschi L; Saller F; Calzavarini S; Angelillo-Scherrer A
Blood; 2018 Mar; 131(12):1360-1371. PubMed ID: 29317453
[TBL] [Abstract][Full Text] [Related]
2. Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
Girard TJ; Lasky NM; Grunz K; Broze GJ
J Thromb Haemost; 2019 Jan; 17(1):149-156. PubMed ID: 30451376
[TBL] [Abstract][Full Text] [Related]
3. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
Hilden I; Lauritzen B; Sørensen BB; Clausen JT; Jespersgaard C; Krogh BO; Bowler AN; Breinholt J; Gruhler A; Svensson LA; Petersen HH; Petersen LC; Balling KW; Hansen L; Hermit MB; Egebjerg T; Friederichsen B; Ezban M; Bjørn SE
Blood; 2012 Jun; 119(24):5871-8. PubMed ID: 22563084
[TBL] [Abstract][Full Text] [Related]
4. Targeting TFPI for hemophilia treatment.
Peterson JA; Maroney SA; Mast AE
Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S28-30. PubMed ID: 27207418
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma.
Gorczyca ME; Nair SC; Jilma B; Priya S; Male C; Reitter S; Knoebl P; Gilbert JC; Schaub RG; Dockal M; McGinness KE; Pabinger I; Srivastava A
J Thromb Haemost; 2012 Aug; 10(8):1581-90. PubMed ID: 22632032
[TBL] [Abstract][Full Text] [Related]
6. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
[TBL] [Abstract][Full Text] [Related]
7. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor.
Wood JP; Ellery PE; Maroney SA; Mast AE
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):169-76. PubMed ID: 24233490
[TBL] [Abstract][Full Text] [Related]
8. Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia.
Maroney SA; Cooley BC; Ferrel JP; Bonesho CE; Nielsen LV; Johansen PB; Hermit MB; Petersen LC; Mast AE
Proc Natl Acad Sci U S A; 2012 Mar; 109(10):3927-31. PubMed ID: 22355108
[TBL] [Abstract][Full Text] [Related]
9. Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy.
Mast AE; Ruf W
J Thromb Haemost; 2022 Jun; 20(6):1290-1300. PubMed ID: 35279938
[TBL] [Abstract][Full Text] [Related]
10. New insights into the biology of tissue factor pathway inhibitor.
Maroney SA; Mast AE
J Thromb Haemost; 2015 Jun; 13 Suppl 1(0 1):S200-7. PubMed ID: 26149025
[TBL] [Abstract][Full Text] [Related]
11. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
Beckman JD; Holle LA; Wolberg AS
J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
[TBL] [Abstract][Full Text] [Related]
12. Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.
Gissel M; Orfeo T; Foley JH; Butenas S
Thromb Res; 2012 Dec; 130(6):948-55. PubMed ID: 22951415
[TBL] [Abstract][Full Text] [Related]
13. The central role of thrombin in bleeding disorders.
Negrier C; Shima M; Hoffman M
Blood Rev; 2019 Nov; 38():100582. PubMed ID: 31164248
[TBL] [Abstract][Full Text] [Related]
14. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia.
Aymonnier K; Kawecki C; Venisse L; Boulaftali Y; Christophe OD; Lenting PJ; Arocas V; de Raucourt E; Denis CV; Bouton MC
Blood; 2019 Nov; 134(19):1632-1644. PubMed ID: 31383642
[TBL] [Abstract][Full Text] [Related]
15. Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP).
Liu T; Scallan CD; Broze GJ; Patarroyo-White S; Pierce GF; Johnson KW
Thromb Haemost; 2006 Jan; 95(1):68-76. PubMed ID: 16543964
[TBL] [Abstract][Full Text] [Related]
16. Antithrombin inhibition using nanobodies to correct bleeding in hemophilia.
O'Sullivan JM; O'Donnell JS
EMBO Mol Med; 2020 Apr; 12(4):e12143. PubMed ID: 32212299
[TBL] [Abstract][Full Text] [Related]
17. Tissue factor-independent inhibition of thrombin generation by tissue factor pathway inhibitor-α.
Thomassen MC; Heinzmann AC; Herfs L; Hartmann R; Dockal M; Scheiflinger F; Hackeng TM; Rosing J
J Thromb Haemost; 2015 Jan; 13(1):92-100. PubMed ID: 25348176
[TBL] [Abstract][Full Text] [Related]
18. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
Lauritzen B; Olling J; Abel KL; Augustsson C; Balling K; Bjelke M; Hegelund AC; Hilden I
J Thromb Haemost; 2019 Mar; 17(3):460-469. PubMed ID: 30614620
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylserine positive microparticles improve hemostasis in in-vitro hemophilia A plasma models.
Zong Y; Pruner I; Antovic A; Taxiarchis A; Vila ZP; Soutari N; Mobarrez F; Chaireti R; Widengren J; Piguet J; Antovic JP
Sci Rep; 2020 May; 10(1):7871. PubMed ID: 32398812
[TBL] [Abstract][Full Text] [Related]
20. Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: studies of spatial dynamics of fibrin clot formation in hemophilia A.
Parunov LA; Soshitova NP; Fadeeva OA; Balandina AN; Kopylov KG; Kumskova MA; Gilbert JC; Schaub RG; McGinness KE; Ataullakhanov FI; Panteleev MA
Thromb Res; 2014 Jan; 133(1):112-9. PubMed ID: 24263002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
